aim study investigate potential protective role fullerenol doxorubicin induced liver toxicity vivo female sprague dawley rats vitro human hepatocellular carcinoma hepg colorectal adenocarcinoma cell lines caco approaches healthy control control chemically induced mammary carcinomas received saline fourth breast cancer injected single dose doxorubicin doxorubicin fullerenol fullerenol min administration doxorubicin fullerenol days treatment rats sacrificed treatment doxorubicin caused serum levels alanine aminotransferase alt aspartate aminotransferase ast lactate dehydrogenase ldh alpha hydroxybutyrate dehydrogenase alpha hbdh levels malondialdehyde mda glutathione gsh glutathione peroxidase gsh px total antioxidant status tas glutathione reductase gr catalase cat superoxide dismutase sod liver tissue effects reduced investigated parameters pre treatment fullerenol mda gsh level hepg caco cell lines continuously treated fullerenol concentrations microg microg aim evaluating modulating activity fullerenol doxorubicin induced hepatotoxicity cell lines simultaneously treated doxorubicin microm microm fullerenol microg microg combinations cells treated microm doxorubicin fullerenol improvement cell capability entire time conclude fullerenol cytotoxic effects hepg oxidative stress cytotoxic effects fullerenol overcome protective role strong antioxidant compound 